VIR US92764N1028

Report

Delayed Nasdaq - 05/25 04:00:01 pm
23.66	USD		+3.68%

02:10a	VIR BIOTECHNOLOGY : Statement of Changes in Beneficial Ownership (Form 4)	PU
05/24	VIR BIOTECHNOLOGY, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
05/20	VIR BIOTECHNOLOGY, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

05/19/2022	05/20/2022	05/23/2022	05/24/2022	05/25/2022	Date
24.93(c)	24.36(c)	24.14(c)	22.82(c)	23.66(c)	Last
1 089 901	741 451	560 958	782 682	712 204	Volume
+9.78%	-2.29%	-0.90%	-5.47%	+3.68%	Change

More quotes

Estimated financial data (e) (USD)

Sales 2022	1 548 M - -
Net income 2022	314 M - -
Net cash position 2022	2 110 M - -
P/E ratio 2022	10,2x
Yield 2022	-

Sales 2023	307 M - -
Net income 2023	-338 M - -
Net cash position 2023	1 801 M - -
P/E ratio 2023	-9,64x
Yield 2023	-

Capitalization	3 132 M 3 132 M -
EV / Sales 2022	0,66x
EV / Sales 2023	4,33x
Nbr of Employees	444
Free-Float	86,6%

More Financials

Company

Vir Biotechnology, Inc. is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. It has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The Company's pipeline consists of...

Sector

Biotechnology & Medical Research

Calendar

08/16

Earnings Release

More about the company

Ratings of Vir Biotechnology, Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

All news about VIR BIOTECHNOLOGY, INC.

02:10a	VIR BIOTECHNOLOGY : Statement of Changes in Beneficial Ownership (Form 4)	PU
05/24	VIR BIOTECHNOLOGY, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
05/20	VIR BIOTECHNOLOGY, INC. : Entry into a Material Definitive Agreement, Termination of a Mat..	AQ
05/20	Correction to Vir Biotechnology Shares Fall 9% Article	DJ
05/20	Vir Biotechnology Shares Fall 9% After Terminating Agreement with WuXi Bio	DJ
05/18	Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details	GL
05/18	Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details	AQ
05/12	HC Wainwright Adjusts Vir Biotechnology Price Target to $125 From $200, Maintains Buy R..	MT
05/11	Pfizer's $11.6 billion Biohaven buy could spark more biotech deals	RE
05/05	Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $1.23B, vs. Street Est of $81..	MT
05/05	VIR BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition an..	AQ
05/05	Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $1.23B, vs. Street Est of $81..	MT
05/05	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Re..	GL
05/05	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Re..	AQ
05/05	Vir Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, ..	CI

More news

News in other languages on VIR BIOTECHNOLOGY, INC.

05/23	UPDATE/MÄRKTE USA/Fester - Präsident Biden sorgt für Hoffnungsschimmer
05/23	MÄRKTE USA/Fester - Präsident Biden sorgt für Hoffnungsschimmer
05/23	MÄRKTE USA/Fester erwartet - Biden weckt China-Fantasie
05/23	MARKT USA/Etwas fester erwartet - Biden weckt China-Fantasie
05/11	Le rachat de Biohaven par Pfizer, pour 11,6 milliards de dollars, pourrait susciter d'a..

More news

Analyst Recommendations on VIR BIOTECHNOLOGY, INC.

05/12	HC Wainwright Adjusts Vir Biotechnology Price Target to $125 From $200, Maintains Buy R..	MT
03/30	HC Wainwright Adjusts Vir Biotechnology's Price Target to $200 From $300, Reiterates Bu..	MT
03/28	Needham Adjusts Vir Biotechnology's Price Target to $45 from $80, Keeps Buy Rating	MT

More recommendations

Provided by Scoopnest.com

Analysis

Pfizer's $11.6 billion Biohaven buy could spark more biotech deals